Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 19 Jul 2024

Ursenbach Axel, Ruch Yvon, Hoellinger Baptiste, Fuchs Anne, Caspar Stéphanie, Jegou Frédérick, Rey David, Fafi-Kremer Samira, Mesplède Thibault, Gantner Pierre

Abstract excerpt

Dolutegravir/lamivudine (DTG/3TC) has a high genetic barrier against the development of human immunodeficiency virus drug resistance. We report 2 cases of R263K + M184V mutations during DTG/3TC failure followed by viral suppression after adherence intervention without treatment change that we attribute to residual drug activity, reduced viral fitness, and robust immune competence.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Heterocyclic Compounds, 3-Ring

Share to Lamivudine

Share to Oxazines

Share to Piperazines

Share to Pyridones

Share to Viral Load

Source

Identifiers

PMID: 38193816
DOI: 10.1093/cid/ciae006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification.PMID 38193816Read ↗

Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.Semantic proximity Read ↗

Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug ResistanceSemantic proximity Read ↗

Selection of Mutations in HIV-1 Nucleocapsid and Integrase in Individuals Living with HIV Experiencing Virologic Failure After Initiating or Switching to Tenofovir-Lamivudine-DolutegravirSemantic proximity Read ↗

A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings.Semantic proximity Read ↗

Dolutegravir plus lamivudine for the treatment of HIV-1 infection.Semantic proximity Read ↗

The Role of Prior HBV Infection and Resistance Mutations on the Efficacy of 3TC/DTG as a Maintenance TherapySemantic proximity Read ↗

What if HIV were unable to develop resistance against a new therapeutic agent?Semantic proximity Read ↗

The dolutegravir failure cohort: a multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocolSemantic proximity Read ↗

Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literatureSemantic proximity Read ↗

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressureSemantic proximity Read ↗

Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.Semantic proximity Read ↗

Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.